Preclinical assessment of inhalational subacute safety of nebulized MP-171 (BromAc®)

Abstract BromAc® (MP-171) is a novel first in class therapeutic agent under investigation for its potential in treating respiratory diseases. Evaluating its safety profile following inhalation is necessary for future clinical application. Here, we evaluated BromAc® safety in an extended subacute sho...

詳細記述

書誌詳細

主要な著者:	Ahmed H. Mekkawy, Md Khalilur Rahman, Krishna Pillai, Samina Badar, Mirela Simic, Javed Akhter, Sarah J. Valle, David L. Morris
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2026-01-01
シリーズ:	BMC Pulmonary Medicine
主題:	BromAc® Cytokines Preclinical Respiratory Extended safety
オンライン･アクセス:	https://doi.org/10.1186/s12890-025-04090-1
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!